Teradan Clinical Trials | Brandon, FL

Research site

(Unclaimed)

Location

910 Oakfield Drive, Brandon, Florida, United States of America

Site insights

Top conditions

Top treatments

Retatrutide

LY3437943

Atomoxetine

AD504

Aroxybutynin

SUVN-G3031

Abivertinib Maleate

STI-2020

Ruxolitinib

R-oxybutynin

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

6 of 19 total trials

A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight (TRIUMPH-1)

The purpose of this study is to evaluate the efficacy and safety of retatrutide in participants who have obesity or overweight (J1I-MC-GZBJ master pr...

Active, not recruiting

Overweight

Obesity

Drug: Retatrutide

Drug: Placebo

Locations recently updated

A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight (TRIUMPH-2)

The purpose of this study is to is to evaluate the efficacy and safety of retatrutide in participants with type 2 diabetes in participants who have o...

Active, not recruiting

Overweight

Obesity

Drug: Placebo

Drug: Retatrutide

A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

The main purpose of this study is to investigate the effect of retatrutide on renal function in participants with overweight or obesity and chronic k...

Enrolling

Overweight or Obesity

CKD

Drug: Placebo

Drug: Retatrutide

Locations recently updated

Continuation Protocol for Obstructive Sleep Apnea (OSA)

The combination drug composed of aroxybutynin and atomoxetine, designated AD109, is being developed by Apnimed for the treatment of obstructive sleep...

Invitation-only

OSA

Drug: Aroxybutynin and Atomoxetine

Dose-finding Study Assessing the Efficacy, Safety, and Pharmacokinetics of Daridorexant in Subjects Aged 10 to < 18 Years With Insomnia Disorder

This study assesses the efficacy, safety, and pharmacokinetics of multiple-dose oral administration of daridorexant in pediatric subjects aged 10 to...

Enrolling

Insomnia

Drug: Daridorexant 10 mg

Drug: Daridorexant 25 mg

Parallel Arm Trial of AD109 and Placebo With Patients With OSA (LunAIRo)

This is a Phase 3 Randomized Double-Blind Placebo-Controlled 1-year Parallel-Arm Study to Compare a Fixed Dose Combination of AD109 to Placebo in Obs...

Active, not recruiting

OSA

Drug: AD109

Drug: Placebo